##gff-version 3
##sequence-region P02489 1 173
P02489	UniProtKB	Chain	1	173	.	.	.	ID=PRO_0000125865;Note=Alpha-crystallin A chain	
P02489	UniProtKB	Chain	1	172	.	.	.	ID=PRO_0000226639;Note=Alpha-crystallin A(1-172)	
P02489	UniProtKB	Chain	1	168	.	.	.	ID=PRO_0000423503;Note=Alpha-crystallin A(1-168)	
P02489	UniProtKB	Chain	1	162	.	.	.	ID=PRO_0000423504;Note=Alpha-crystallin A(1-162)	
P02489	UniProtKB	Domain	52	164	.	.	.	Note=sHSP;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00285	
P02489	UniProtKB	Metal binding	79	79	.	.	.	Note=Zinc 1;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P02489	UniProtKB	Metal binding	100	100	.	.	.	Note=Zinc 2;Ontology_term=ECO:0000250;evidence=ECO:0000250	
P02489	UniProtKB	Metal binding	102	102	.	.	.	Note=Zinc 2;Ontology_term=ECO:0000250;evidence=ECO:0000250	
P02489	UniProtKB	Metal binding	107	107	.	.	.	Note=Zinc 1;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P02489	UniProtKB	Metal binding	115	115	.	.	.	Note=Zinc 1;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P02489	UniProtKB	Site	1	1	.	.	.	Note=Susceptible to oxidation	
P02489	UniProtKB	Site	18	18	.	.	.	Note=Susceptible to oxidation	
P02489	UniProtKB	Site	34	34	.	.	.	Note=Susceptible to oxidation	
P02489	UniProtKB	Site	138	138	.	.	.	Note=Susceptible to oxidation	
P02489	UniProtKB	Modified residue	1	1	.	.	.	Note=N-acetylmethionine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:817940;Dbxref=PMID:817940	
P02489	UniProtKB	Modified residue	6	6	.	.	.	Note=Deamidated glutamine%3B partial;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9068373;Dbxref=PMID:9068373	
P02489	UniProtKB	Modified residue	45	45	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9068373;Dbxref=PMID:9068373	
P02489	UniProtKB	Modified residue	50	50	.	.	.	Note=Deamidated glutamine%3B partial;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9068373;Dbxref=PMID:9068373	
P02489	UniProtKB	Modified residue	70	70	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:22120592,ECO:0000269|PubMed:9655350;Dbxref=PMID:22120592,PMID:9655350	
P02489	UniProtKB	Modified residue	90	90	.	.	.	Note=Deamidated glutamine%3B partial;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9068373;Dbxref=PMID:9068373	
P02489	UniProtKB	Modified residue	99	99	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22120592;Dbxref=PMID:22120592	
P02489	UniProtKB	Modified residue	101	101	.	.	.	Note=Deamidated asparagine%3B partial;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:8175657,ECO:0000269|PubMed:9068373,ECO:0000269|PubMed:9543632,ECO:0000269|PubMed:9655350;Dbxref=PMID:8175657,PMID:9068373,PMID:9543632,PMID:9655350	
P02489	UniProtKB	Modified residue	122	122	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:8175657,ECO:0000269|PubMed:8759518,ECO:0000269|PubMed:9068373;Dbxref=PMID:8175657,PMID:8759518,PMID:9068373	
P02489	UniProtKB	Modified residue	123	123	.	.	.	Note=Deamidated asparagine%3B partial;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18754677;Dbxref=PMID:18754677	
P02489	UniProtKB	Modified residue	147	147	.	.	.	Note=Deamidated glutamine%3B partial;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9068373;Dbxref=PMID:9068373	
P02489	UniProtKB	Glycosylation	162	162	.	.	.	Note=O-linked (GlcNAc) serine;Ontology_term=ECO:0000250;evidence=ECO:0000250	
P02489	UniProtKB	Disulfide bond	131	142	.	.	.	Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:8175657,ECO:0000269|PubMed:9068373;Dbxref=PMID:8175657,PMID:9068373	
P02489	UniProtKB	Natural variant	12	12	.	.	.	ID=VAR_070032;Note=In CTRCT9. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23508780;Dbxref=dbSNP:rs397515624,PMID:23508780	
P02489	UniProtKB	Natural variant	21	21	.	.	.	ID=VAR_046892;Note=In CTRCT9%3B associated with macular hypoplasia and a generally hypopigmented fundus. R->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16453125;Dbxref=PMID:16453125	
P02489	UniProtKB	Natural variant	49	49	.	.	.	ID=VAR_038375;Note=In CTRCT9%3B nuclear cataract. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:14512969;Dbxref=dbSNP:rs74315441,PMID:14512969	
P02489	UniProtKB	Natural variant	105	105	.	.	.	ID=VAR_036564;Note=In a breast cancer sample%3B somatic mutation. D->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16959974;Dbxref=PMID:16959974	
P02489	UniProtKB	Natural variant	116	116	.	.	.	ID=VAR_003819;Note=In CTRCT9%3B zonular central nuclear cataract%3B reduced chaperone-like activity and increased membrane-binding capacity. R->C;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11123904,ECO:0000269|PubMed:9467006;Dbxref=dbSNP:rs74315439,PMID:11123904,PMID:9467006	
P02489	UniProtKB	Natural variant	116	116	.	.	.	ID=VAR_046893;Note=In CTRCT9%3B reverse phase-high-performance liquid chromatography suggests an increase hydrophobicity of the mutant protein%3B loss of chaperone activity of the mutant is seen in DL-dithiothreitol-induced insulin aggregation assay%3B fast protein liquid chromatography purification shows that the mutant protein has increased binding affinity to lysozyme. R->H;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18302245,ECO:0000269|PubMed:18407550;Dbxref=dbSNP:rs121912973,PMID:18302245,PMID:18407550	
P02489	UniProtKB	Mutagenesis	123	123	.	.	.	Note=Impairs chaperone activity. N->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18754677;Dbxref=PMID:18754677	
P02489	UniProtKB	Sequence conflict	45	45	.	.	.	Note=S->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P02489	UniProtKB	Sequence conflict	153	155	.	.	.	Note=THA->HT;Ontology_term=ECO:0000305;evidence=ECO:0000305	
